In the current model, PD-L1 is expressed on DCs in lymph nodes (Supplementary Fig. S1), and it is thought that blocking PD-L1 expressed on DCs in the lymph nodes with antibodies could promote priming and enhance anti-tumor activity. Here, CD274 is linked to neoplasm.